Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARC-520 extension study in chronic hepatitis B
2014-004201-33Phase 2Completed
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Mar 2016
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of ARC-520 in Chronic Hepatitis B (CHB) (2 arms), sponsored by Arrowhead Pharmaceuticals. Primary endpoints: Change from baseline to Day 113 in log quantitative HBsAg and Proportion achieving 1-log HBsAg reduction at week 36. Started Mar 2016; status: completed.
02
Drugs
ARC-520
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2014-004201-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004201-33.